Literature DB >> 25531281

Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.

H Nakasone1, T Fukuda2, J Kanda3, T Mori4, S Yano5, T Kobayashi6, K Miyamura7, T Eto8, H Kanamori9, K Iwato10, N Uchida11, S Mori12, T Nagamura-Inoue13, T Ichinohe14, Y Atsuta15, T Teshima16, M Murata17.   

Abstract

The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.

Entities:  

Mesh:

Year:  2014        PMID: 25531281     DOI: 10.1038/bmt.2014.293

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

1.  50 years of allogeneic bone-marrow transplantation.

Authors:  Ray Powles
Journal:  Lancet Oncol       Date:  2010-04       Impact factor: 41.316

2.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

Review 3.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

5.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

6.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Authors:  Theresa Hahn; Philip L McCarthy; Mei-Jie Zhang; Dan Wang; Mukta Arora; Haydar Frangoul; Robert Peter Gale; Gregory A Hale; John Horan; Luis Isola; Richard T Maziarz; Jon J van Rood; Vikas Gupta; Joerg Halter; Vijay Reddy; Pierre Tiberghien; Mark Litzow; Claudio Anasetti; Stephen Pavletic; Olle Ringdén
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

7.  Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Authors:  Makoto Murata; Hideki Nakasone; Junya Kanda; Takahiko Nakane; Tatsuo Furukawa; Takahiro Fukuda; Takehiko Mori; Shuichi Taniguchi; Tetsuya Eto; Kazuteru Ohashi; Masayuki Hino; Masami Inoue; Hiroyasu Ogawa; Yoshiko Atsuta; Tokiko Nagamura-Inoue; Hiromasa Yabe; Yasuo Morishima; Hisashi Sakamaki; Ritsuro Suzuki
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-12       Impact factor: 5.742

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 9.  High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink?

Authors:  Mohamad Mohty; Florent Malard; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-20       Impact factor: 5.742

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  19 in total

1.  Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.

Authors:  Tomoaki Ueda; Tomoyasu Jo; Kazuya Okada; Yasuyuki Arai; Takayuki Sato; Takeshi Maeda; Tatsuhito Onishi; Yasunori Ueda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

Review 2.  Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.

Authors:  Hideki Nakasone; Bita Sahaf; David B Miklos
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

3.  Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality.

Authors:  Celalettin Ustun; Todd E DeFor; Fatma K Karadag; Hyun Don Yun; Sunita Nathan; Claudio G Brunstein; Bruce R Blazar; Daniel J Weisdorf; Shernan G Holtan; Khalid Amin
Journal:  Blood Adv       Date:  2020-05-26

4.  Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients.

Authors:  Emma E Ilett; Mette Jørgensen; Marc Noguera-Julian; Jens Christian Nørgaard; Gedske Daugaard; Marie Helleberg; Roger Paredes; Daniel D Murray; Jens Lundgren; Cameron MacPherson; Joanne Reekie; Henrik Sengeløv
Journal:  Blood Adv       Date:  2020-11-24

Review 5.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

6.  Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Jelena Eremija; Nicolas Larmonier; Yi Zeng; Emmanuel Katsanis
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-13       Impact factor: 5.742

7.  Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.

Authors:  Stephen P Persaud; Julie K Ritchey; Sena Kim; Sora Lim; Peter G Ruminski; Matthew L Cooper; Michael P Rettig; Jaebok Choi; John F DiPersio
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

8.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

Authors:  Satoshi Kaito; Yujiro Nakajima; Konan Hara; Takashi Toya; Tetsuya Nishida; Naoyuki Uchida; Junichi Mukae; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Kazuhiro Ikegame; Yuta Katayama; Takuro Kuriyama; Junya Kanda; Yoshiko Atsuta; Masao Ogata; Ayumi Taguchi; Kazuteru Ohashi
Journal:  Blood Adv       Date:  2020-03-24

9.  Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children.

Authors:  Christopher E Dandoy; Stella M Davies; Kwang Woo Ahn; Yizeng He; Anders E Kolb; John Levine; Stephanie Bo-Subait; Hisham Abdel-Azim; Neel Bhatt; Joseph Chewing; Shahinaz Gadalla; Nicholas Gloude; Robert Hayashi; Nahal R Lalefar; Jason Law; Margaret MacMillan; Tracy O'Brien; Timothy Prestidge; Akshay Sharma; Peter Shaw; Lena Winestone; Mary Eapen
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

10.  Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.

Authors:  Oscar B Lahoud; Sean M Devlin; Molly A Maloy; Lindsey E Roeker; Parastoo B Dahi; Doris M Ponce; Boglarka Gyurkocza; Guenther Koehne; James W Young; Hugo R Castro-Malaspina; Juliet N Barker; Esperanza B Papadopoulos; Ann A Jakubowski; Andrew D Zelenetz; Anthony R Mato; Sergio A Giralt; Miguel A Perales; Craig S Sauter
Journal:  Blood Adv       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.